Arrowhead Pharmaceuticals, Inc. (ARWR) income statement
NASDAQ · Healthcare · Biotechnology · 711 employees · CEO Christopher R. Anzalone
- Price
- $59.90 -0.98%
- Market cap
- $8.46B
- Enterprise value
- $9.27B
- Last report
- Q3 '26 filed 2026-08-04
- Next report
- 2026-11-24 EPS est. -$1.52
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $75.3M for Q3 '26 (+171.0% year on year), operating income of -$170M (-226.0% of revenue) and net income of -$194M. Over the last four quarters revenue was $669M.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $3.55M | $0 | $0 | $0 | $2.5M | $543M | $27.8M | $256M | $264M | $73.7M | $75.3M | |
| Cost of revenue | $3.86M | $4.26M | $4.53M | $4.78M | $5.03M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $12.2M | -$712K | -$4.53M | -$4.78M | -$5.03M | $2.5M | $543M | $27.8M | $256M | $264M | $73.7M | $75.3M | |
| Research & development | $96.4M | $113M | $97M | $148M | $131M | $137M | $133M | $162M | $175M | $177M | $173M | $198M | |
| General & administrative | $24.2M | $23.2M | $24.6M | $23.2M | $25.8M | $26.4M | $27.9M | $30.4M | $37.2M | $45.5M | $41.2M | $0 | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $509K | $511K | $505K | $503K | $504K | $500K | $0 | |
| Operating expenses | $121M | $136M | $122M | $171M | $157M | $164M | $162M | $193M | $212M | $223M | $215M | $245M | |
| Operating income | -$108M | -$137M | -$126M | -$176M | -$162M | -$161M | $381M | -$166M | $44.1M | $40.8M | -$141M | -$170M | |
| Interest income | $3.89M | $2.8M | $6.25M | $6.5M | $7.17M | $7.6M | $9.62M | $11M | $9.05M | $9.69M | $16.9M | $16.9M | |
| Interest expense | $5.26M | $5.37M | $7.24M | $5.09M | $14.6M | $21.6M | $21.6M | $24.4M | $21.7M | $22.5M | $23.8M | $24.6M | |
| Other non-operating income (gains on investments, FX ...) | -$4.6M | -$3.22M | -$6.44M | -$7.26M | -$4.05M | -$7.94M | -$10.1M | -$10.8M | -$13.7M | -$9.97M | -$27.5M | -$15.8M | |
| Total non-operating income | -$660K | -$2.14M | -$805K | $2.16M | -$10.6M | -$13.7M | -$11.6M | -$13.5M | -$7.99M | -$12.5M | $3.7M | -$8.81M | |
| Income before tax | -$109M | -$139M | -$127M | -$174M | -$173M | -$175M | $370M | -$179M | $36.1M | $28.3M | -$138M | -$179M | |
| Income tax | $2.03M | -$3.31M | $0 | $0 | $546K | $103K | $1.75M | -$437K | $20M | $29K | $7K | $11K | |
| Net income | -$110M | -$133M | -$125M | -$171M | -$171M | -$173M | $370M | -$175M | -$23.8M | $30.8M | -$133M | -$194M | |
| EPS (basic) | -$1.02 | -$1.24 | -$1.02 | -$1.38 | -$1.40 | -$1.39 | $2.78 | -$1.26 | -$0.17 | $0.22 | -$0.93 | -$1.36 | |
| EPS (diluted) | -$1.02 | -$1.24 | -$1.02 | -$1.38 | -$1.40 | -$1.39 | $2.75 | -$1.26 | -$0.17 | $0.22 | -$0.93 | -$1.36 | |
| Shares (basic, weighted) | 107M | 107M | 123M | 124M | 122M | 125M | 133M | 139M | 136M | 140M | 142M | 143M | |
| Shares (diluted, weighted) | 107M | 107M | 123M | 124M | 122M | 125M | 134M | 139M | 136M | 141M | 142M | 143M | |
| Depreciation & amortization | $3.86M | $4.26M | $4.53M | $4.78M | $5.03M | $5.24M | $6.08M | $6.22M | $6.39M | $6.39M | $6.37M | $6.66M | |
| EBITDA | -$99.9M | -$129M | -$115M | -$164M | -$153M | -$148M | $397M | -$148M | $64.2M | $57.2M | -$107M | -$148M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158K | $31.4M | $16.1M | $169M | $88M | $138M | $243M | $241M | $3.55M | $829M | |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $10.4M | $12.5M | $18.6M | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $138M | $233M | $228M | -$15M | $829M | |
| Research & development | $41.5M | $46.3M | $48.3M | $76.6M | $124M | $206M | $289M | $342M | $489M | $607M | |
| General & administrative | $23.6M | $17.5M | $19.1M | $26.6M | $52.3M | $81M | $124M | $90.9M | $96.8M | $122M | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.03M | |
| Operating expenses | $82.5M | $63.7M | $67.4M | $103M | $175M | $287M | $411M | $433M | $586M | $731M | |
| Operating income | -$81.7M | -$37M | -$55.9M | $61.2M | -$93.2M | -$149M | -$179M | -$205M | -$601M | $98.3M | |
| Interest income | $266K | $415K | $1.05M | $6.96M | $9.19M | $6.12M | $5.03M | $15.3M | $22.7M | $37.3M | |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $18.3M | $32.4M | $89.4M | |
| Other non-operating income (gains on investments, FX ...) | -$2.05M | $0 | $0 | $0 | $0 | -$8.19M | -$5.8M | -$16.8M | -$21M | -$42.5M | |
| Total non-operating income | $22.1K | $2.62M | $1.49M | $6.96M | $8.61M | $8.19M | $5.8M | -$1.49M | -$11.4M | -$46.8M | |
| Income before tax | -$81.7M | -$34.4M | -$54.4M | $68.1M | -$84.6M | -$141M | -$173M | -$206M | -$612M | $51.5M | |
| Income tax | $2.4K | $2.4K | $2.4K | $174K | $2K | $2K | $3.79M | $2.78M | -$2.77M | $21.4M | |
| Net income | -$81.7M | -$34.4M | -$54.5M | $68M | -$84.6M | -$141M | -$176M | -$205M | -$599M | -$1.63M | |
| EPS (basic) | -$1.34 | -$0.47 | -$0.65 | $0.72 | -$0.84 | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 | |
| EPS (diluted) | -$1.34 | -$0.47 | -$0.65 | $0.69 | -$0.84 | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 | |
| Shares (basic, weighted) | 61M | 73.1M | 83.6M | 93.9M | 101M | 104M | 105M | 107M | 120M | 134M | |
| Shares (diluted, weighted) | 61.1M | 73.9M | 83.6M | 98.6M | 101M | 104M | 105M | 107M | 120M | 134M | |
| Depreciation & amortization | $3.26M | $4.69M | $4.7M | $4.44M | $5.94M | $8.27M | $10.4M | $12.5M | $18.6M | $23.9M | |
| EBITDA | -$76.4M | -$32.3M | -$51.2M | $65.6M | -$87.2M | -$133M | -$162M | -$176M | -$562M | $165M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02